Literature DB >> 25419350

Exclusion of IL-21 in the pathogenesis of OVA-induced asthma in mice.

Sheng Cheng1, Huilong Chen1, Aili Wang1, Hansvin Bunjhoo1, Yong Cao1, Jungang Xie1, Yongjian Xu1, Weining Xiong1.   

Abstract

Asthma is characterized by airway inflammation, mucus overproduction, and airway hyperreactivity. Cytokines, especially T helper 2-derived cytokines interleukin (IL)-4, IL-5, and IL-13, are involved in the pathogenesis of asthma. IL-21 has a variety of effects on the immune system. However, the contribution of IL-21 to the development of allergic diseases is currently controversial. The aim of this study was to investigate the effect of IL-21 on asthma airway inflammation in vivo. A murine ovalbumin (OVA)-induced allergic asthma model was used. The concentration of IL-21 in the bronchoalveolar lavage fluid (BALF) of mice was evaluated by enzyme-linked immunosorbent assay. BALF cellularity, lung histopathology, and sera IgE levels were compared between the normal control group, OVA sensitization/challenge group, and OVA sensitization/challenge plus IL-21-administered group. An OVA-induced allergic rhinitis model with IL-21 was used as a positive control and the infiltration of eosinophils in the nasal mucosa was evaluated. The concentration of IL-21 in the BALF was lower in the asthmatic group compared with the normal control group. However, no significant differences in airway eosinophilia, lung histopathology, and sera IgE levels were observed between the OVA sensitization/challenge group and OVA sensitization/challenge plus IL-21-administered group. Decreased eosinophilic infiltration of nasal mucosa was observed in the positive control allergic rhinitis model administered IL-21 during the challenge period. Exogenous administration of IL-21 alone may not alleviate allergic lung inflammation. The role of IL-21 in allergic lung inflammation needs further research.

Entities:  

Keywords:  Allergic lung inflammation; asthma; challenge; cytokine; interleukin-21

Year:  2014        PMID: 25419350      PMCID: PMC4238472     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  31 in total

Review 1.  Immunologic basis of antigen-induced airway hyperresponsiveness.

Authors:  M Wills-Karp
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

2.  Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression.

Authors:  Jamila Chakir; Joanne Shannon; Sophie Molet; Motonori Fukakusa; Jack Elias; Michel Laviolette; Louis-Philippe Boulet; Qutayba Hamid
Journal:  J Allergy Clin Immunol       Date:  2003-06       Impact factor: 10.793

3.  Interleukin-21 expanded NKDC in vitro reduces the B16F10 tumor growth in vivo.

Authors:  A P Souza; C Bonorino; S P Muraro; L C Rodrigues
Journal:  Cytokine       Date:  2012-10-23       Impact factor: 3.861

4.  IL-21 administration into the nostril alleviates murine allergic rhinitis.

Authors:  Yayoi Hiromura; Tsunao Kishida; Hiroshi Nakano; Takemitsu Hama; Jiro Imanishi; Yasuo Hisa; Osam Mazda
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

5.  IL-21 receptor signalling partially mediates Th2-mediated allergic airway responses.

Authors:  S Lajoie; I Lewkowich; N S Herman; A Sproles; J T Pesce; T A Wynn; M J Grusby; Q Hamid; M Wills-Karp
Journal:  Clin Exp Allergy       Date:  2014-07       Impact factor: 5.018

6.  A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma.

Authors:  Yui-Hsi Wang; Kui Shin Voo; Bo Liu; Chun-Yu Chen; Burcin Uygungil; William Spoede; Jonathan A Bernstein; David P Huston; Yong-Jun Liu
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

7.  Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.

Authors:  Teresa M Petrella; Richard Tozer; Karl Belanger; Kerry J Savage; Ralph Wong; Michael Smylie; Suzanne Kamel-Reid; Victor Tron; Bingshu E Chen; Naomi N Hunder; Linda Hagerman; Wendy Walsh; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

8.  Requirement for IL-13 independently of IL-4 in experimental asthma.

Authors:  G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

Review 9.  The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Curr Opin Immunol       Date:  2008-06-12       Impact factor: 7.486

10.  IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.

Authors:  Saskia J A M Santegoets; Annelies W Turksma; Megan M Suhoski; Anita G M Stam; Steve M Albelda; Erik Hooijberg; Rik J Scheper; Alfons J M van den Eertwegh; Winald R Gerritsen; Daniel J Powell; Carl H June; Tanja D de Gruijl
Journal:  J Transl Med       Date:  2013-02-12       Impact factor: 5.531

View more
  3 in total

1.  IL-21 does not involve in OVA-induced airway remodeling and chronic airway inflammation.

Authors:  Huilong Chen; Sheng Cheng; Aili Wang; Hansvin Bunjhoo; Yong Cao; Jungang Xie; Congyi Wang; Yongjian Xu; Weining Xiong
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2.

Authors:  Huilong Chen; Xiangqin Xu; Jieming Teng; Sheng Cheng; Hansvin Bunjhoo; Yong Cao; Jin Liu; Jungang Xie; Congyi Wang; Yongjian Xu; Weining Xiong
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 3.  T Follicular Helper Cell Subsets and the Associated Cytokine IL-21 in the Pathogenesis and Therapy of Asthma.

Authors:  Fang Gong; Ting Zheng; Pengcheng Zhou
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.